

CAMSON BIO TECHNOLOGIES LIMITED
STATEMENT OF STANDALONE AND CONSOLIDATED AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2016

Rupees in Lakhs

Sl. No.	Particulars	Standalone				Consolidated			
		Quarter ended		Year ended		Year ended		Year ended	
		31 March, 2016 (Refer Note: 7)	31 December, 2015 (Unaudited)	31 March, 2015 (Audited) Refer Note:3	31 March, 2016 (Refer Note: 7)	31 March, 2015 (Audited) Refer Note:3	31 March, 2016 (Refer Note: 7)	31 March, 2015 (Audited) Refer Note:3	31 March, 2016 (Refer Note: 7)
1	Income from Operations								
	(a) Net sales / income from Operations (Net of Excise duty)	(563.45)	454.55	3,749.69	2,540.33	16,938.15	6,211.53	20,302.02	
	(b) Other Operating Income	(563.45)	454.55	3,749.69	2,540.33	16,938.15	6,211.53	20,302.02	
2	Total income from Operations (net)								
	Expenses								
	(a) Cost of Materials consumed	32.50	176.69	303.03	574.81	3,412.41	984.06	3,716.18	
	(b) Purchase of stock-in-trade			492.43		2,596.99	2,527.02	5,407.79	
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	121.27	(112.86)	1,452.98	(91.23)	1,634.09	14.36	1,563.12	
	(d) Employee benefits expenses	170.60	244.87	337.64	992.40	1,293.52	1,329.23	1,530.40	
	(e) Depreciation and amortisation expenses	1,385.93	239.28	334.75	2,171.77	1,340.28	2,322.41	1,399.67	
	(f) Other expenses (Any Item exceeding 10% of the total expenses relating to continuing operations to be shown separately)								
	-Geo - Climatic Trials	99.84	58.11	258.64	402.86	724.34	402.86	724.34	
	-Selling and Promotion Expenses	147.10	428.55	372.43	969.43	3,306.15	976.99	3,301.18	
	-Other Expenses	283.58	269.41	853.56	1,129.92	2,365.17	1,463.68	2,617.92	
	Total Expenses	2,240.82	1,304.05	4,405.46	6,149.96	16,672.95	10,020.61	20,240.59	
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(2,804.27)	(849.50)	(655.77)	(3,609.63)	265.20	(3,809.08)	61.42	
4	Other Income	31.50	(4.28)	588.39	115.75	635.22	123.41	642.17	
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	(2,772.77)	(853.78)	(67.38)	(3,493.88)	900.42	(3,685.67)	703.69	
6	Finance Cost	206.34	115.75	161.21	498.90	395.63	665.37	494.62	
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	(2,979.11)	(969.53)	(228.59)	(3,992.78)	504.79	(4,351.04)	209.08	
8	Exceptional Items								
9	Profit / (Loss) from ordinary activities before tax (7 ± 8)	(2,979.11)	(969.53)	(228.59)	(3,992.78)	504.79	(4,351.04)	209.08	
10	Tax Expenses	(277.60)	44.38	85.88	(209.30)	196.56	(208.78)	197.87	
11	Net Profit / (Loss) from Ordinary Activities after tax (9 ± 10)	(2,701.51)	(1,013.91)	(314.47)	(3,783.48)	308.23	(4,142.26)	11.21	
12	Extraordinary Items (net of tax expenses)								
13	Net Profit / (Loss) for the period (11 ± 12)	(2,701.51)	(1,013.91)	(314.47)	(3,783.48)	308.23	(4,142.26)	11.21	
14	Share of Profit / (loss) of associates								
15	Minority interest						(198.37)	(182.33)	
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15)	(2,701.51)	(1,013.91)	(314.47)	(3,783.48)	308.23	(3,943.89)	193.53	
17	Paid up Equity Share Capital [Face value per Share is Rs. 10/-]	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	
18	Reserves excluding Revaluation Reserve as per Balance Sheet of the previous accounting year								
19.i	Earnings per share (before extraordinary items) (of Rs.10 /- each) (not annualised):					23,398.49	7,162.92	23,324.65	
	(a) Basic	(9.01)	(3.38)	(1.10)	(12.61)	1.07	(13.15)	0.67	
	(b) diluted	(9.01)	(3.38)	(1.10)	(12.61)	1.07	(13.15)	0.67	
19.ii	Earnings per share (after extraordinary items) (of Rs.10 /- each) (not annualised):					1.07	(13.15)	0.87	
	(a) Basic	(9.01)	(3.38)	(1.10)	(12.61)	1.07	(13.15)	0.87	
	(b) Diluted	(9.01)	(3.38)	(1.10)	(12.61)	1.07	(13.15)	0.87	

See accompanying note to the Financial Results





[Handwritten signature]

REPORT OF SEGMENT-WISE STANDALONE & CONSOLIDATED REVENUE, RESULTS AND CAPITAL EMPLOYED FOR QUARTER AND YEAR ENDED AS ON MARCH 31, 2016

Rupees in Lakhs

Sl. No.	Particulars	Standalone				Consolidated		
		Quarter Ended		Year ended		Year ended		
		31 March, 2016 (Refer Note: 7)	31 December, 2015 (Unaudited)	31 March, 2015 (Audited) Refer Note:3	31 March, 2016 (Refer Note: 7)	31 March, 2015 (Audited) Refer Note:3	31 March, 2016 (Refer Note: 7)	31 March, 2015 (Audited) Refer Note:3
1	Segment Revenue							
	a) Seeds and Vegetables	-	3,043.75	10,943.05	-	2,528.69	14,153.83	5,995.10
	b) Agri Biotech Products	(563.45)	705.94	5,995.10	2,540.33	3,682.84	5,995.10	186.87
	c) Unallocated	(563.45)	454.55	16,938.15	2,540.33	6,211.53	20,335.80	-
	Total							
	Less: Intersegment Revenue							
	Net Sales/ Income from Operation		454.55	16,938.15	2,540.33	6,211.53	20,335.80	-
2	Segment Results							
	Profit (+) / Loss (-) before tax and interest from each segment							
	a) Seeds and Vegetables	-	565.05	1,381.70	-	(3,493.88)	1,137.20	511.96
	b) Agri Biotech Products	(2,772.78)	(853.78)	(301.62)	(3,493.88)	(191.79)	(38.13)	(3,685.67)
	c) Unallocated	(2,772.78)	(853.78)	263.43	(3,493.88)	1,893.66	1,621.03	993.23
	Total							
	Less: (i) Other Net unallocable income /expenses							
	(ii) Finance Cost	206.34	115.75	161.21	498.90	665.37	408.73	-
	Total Profit before Tax	(2,979.12)	(969.53)	(228.59)	(3,992.78)	504.79	209.07	(4,351.04)
3	Capital Employed							
	(Segment Assets-Segment liabilities)							
	a) Seeds and Vegetables	-	-	14,254.81	-	14,254.81	14,153.15	9,025.30
	b) Agri Biotech products	10,214.34	13,125.16	9,025.30	10,214.34	9,954.12	9,025.30	3,144.19
	c) Unallocated	-	-	3,118.36	-	-	-	-
	TOTAL	10,214.34	13,125.16	26,398.47	10,214.34	9,954.12	26,322.64	-




AM

STATEMENT OF ASSETS AND LIABILITIES UNDER CLAUSE 41(v) OF THE LISTING AGREEMENT

Rupees in Lakhs

Sl. No	PARTICULARS	Standalone			Consolidated		
		March 31, 2016	March 31, 2015	March 31, 2016	March 31, 2015	March 31, 2016	March 31, 2015
		[Refer Note: 7]	[Audited]	[Refer Note: 7]	[Audited]	[Refer Note: 7]	[Audited]
			Refer Note:3			Refer Note:3	
A	EQUITY AND LIABILITIES						
1	Shareholders' Funds						
	(a) Share Capital	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98	2,999.98
	(b) Reserves and Surplus	7,423.65	23,398.49	7,162.92	23,324.65	23,324.65	23,324.65
	Sub Total - Shareholders Funds	10,423.63	26,398.47	10,162.90	26,324.63	26,324.63	26,324.63
2	Minority Interest	-	-	225.80	-	292.69	-
3	Non-Current Liabilities						
	(a) Long Term Borrowings	948.55	494.81	1,088.26	726.23	726.23	726.23
	(b) Other Long term Liabilities	228.85	244.97	228.85	244.97	244.97	244.97
	(c) Deferred Tax Liabilities (Net)	-	177.97	-	177.97	177.97	177.97
	(d) Long Term Provisions	55.39	88.31	56.27	93.86	93.86	93.86
	Sub Total - Non Current liabilities	1,232.79	1,006.06	1,383.38	1,243.03	1,243.03	1,243.03
4	Current Liabilities						
	(a) Short Term Borrowings	3,638.35	3,169.84	4,810.28	3,840.63	3,840.63	3,840.63
	(b) Trade Payables	-	-	-	-	-	-
	Due to Micro, Small and Medium Enterprises	788.02	1,066.45	1,589.42	1,962.77	1,962.77	1,962.77
	Due to others	844.36	615.68	1,062.70	1,000.55	1,000.55	1,000.55
	(c) Other Current Liabilities	294.78	284.14	295.73	284.75	284.75	284.75
	(d) Short Term Provisions	5,545.51	5,136.21	7,758.13	7,088.70	7,088.70	7,088.70
	Sub Total - Current Liabilities	17,201.93	32,540.74	19,530.21	34,949.05	34,949.05	34,949.05
	TOTAL						
B	ASSETS						
1	Non-Current Assets						
	(a) Fixed Assets						
	(i) Tangible Assets	9,395.46	11,110.80	10,619.92	12,417.66	12,417.66	12,417.66
	(ii) Intangible Assets	1,166.45	2,743.77	1,301.45	2,919.41	2,919.41	2,919.41
	(iii) Intangible asset under development	-	-	1.36	0.95	0.95	0.95
	(b) Good will on consolidation	597.91	0.83	0.25	0.25	0.25	0.25
	(c) Non-Current Investments	118.14	-	118.15	-	-	-
	(d) Deferred tax assets (Net) [Refer note 26.15]	3,256.71	768.48	3,256.71	168.48	168.48	168.48
	(e) Long Term Loans & Advances	7.50	-	13.24	-	-	-
	(f) Other non-current assets	14,542.17	14,623.98	15,311.08	15,512.62	15,512.62	15,512.62
	Sub Total - Non-Current Assets	19,530.21	32,540.74	19,530.21	34,949.05	34,949.05	34,949.05
2	Current Assets						
	(a) Inventories	923.94	2,533.60	1,088.86	2,797.10	2,797.10	2,797.10
	(b) Trade Receivables	1,659.71	14,724.85	2,862.25	15,951.13	15,951.13	15,951.13
	(c) Cash & Cash Equivalents	30.21	102.90	59.25	145.64	145.64	145.64
	(d) Short Term Loans & Advances	45.90	555.41	208.77	542.56	542.56	542.56
	Sub Total -Current Assets	2,659.76	17,916.76	4,219.13	19,436.43	19,436.43	19,436.43
	TOTAL						
		17,201.93	32,540.74	19,530.21	34,949.05	34,949.05	34,949.05



Notes :

- 1 The above Financial Results were reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at its meeting held on May 30, 2016.
- 2 The nature of the Company's business being related to agriculture and the composition of income varying due to the underlying environmental and market conditions, the results of the Company on quarter to quarter can vary significantly and are therefore not comparable.
- 3 During the year the Company received an order dated 31st July 2015 from the High Court of Karnataka for demerger of Seeds and Vegetables business of the Company with an appointed date of 1st April, 2014. Accordingly the above results have been presented for Agri Biotech business. Consequently the Company operates in a single segment i.e. Agri Biotech and the results relating to previous quarter/period/year are not comparable.



The profit/ (loss) of the demerged business included in the above is as follows:

Particulars	Standalone				Consolidated	
	Quarter Ended		Year ended		Year ended	
	31 March, 2016	31 December, 2015	31 March, 2015	31 March, 2016	31 March, 2015	31 March, 2016
Seeds and Vegetables (Profit before tax, finance cost and exceptional items)	Nil	Nil	Nil	Nil	1,381.70	1,437.20

- 4 During the year, the company has received communication from shareholders to conduct a forensic audit on the financial matters of the Company. The company has replied to the shareholder requesting specific facts and scope/areas for forensic audit.
The Company's Board of Directors on meeting held on May 30, 2016 has proposed to carry out forensic audit by appointing an independent committee/legal counsel to decide the scope and the areas of forensic audit. Accordingly, the company is of the view that material adjustments or disclosures, if any, would be considered after conclusion of the forensic audit.
- 5 The Company is in the process of appointing of Company Secretary as required under Section 203 of the Companies Act, 2013.
- 6 The above results include results for the quarter ended March 31, 2016 being the balancing figure between audited figures in respect of full financial year and the published year to date figure upto the third quarter of the current financial year which were reviewed by the statutory auditors of the company.
- 7 The auditors have expressed a disclaimer of opinion on financial statements for the year ended March 31, 2016, which is explained by management in the above mentioned note no. 4.
- 8 Figures for the previous periods/years have been reclassified wherever necessary to conform to the classification of the current year.



Date : May 30, 2016
Place : Bengaluru

For and on behalf of the Board of Directors

 Veerendra Kumar Singh
 Managing Director

 Akhail Narayan Singh
 Director

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF CAMSON BIO TECHNOLOGIES LIMITED

1. We were engaged to audit the accompanying Statement of Standalone Financial Results of **CAMSON BIO TECHNOLOGIES LIMITED** ("the Company") for the year ended March 31, 2016 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements. The Company's Management is required to prepare the said financial statements in accordance with the Accounting standards prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Refer Note 4 of the Statement.
2. Our responsibility is to express an opinion on the Statement based on conducting our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India.

Because of the matter described in paragraph 3 below, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion.

3. We draw attention to Note 4 of the Statement. The Company has received communication from shareholders alleging certain issues relating to financial matters of the Company and have requested to conduct a forensic audit. The Company has replied to the shareholders requesting specific facts and scope/areas for the forensic audit. The Company's Board of Directors has proposed to carry out a forensic audit by appointing an independent committee/legal counsel. As stated in the aforesaid Note, the Company is of the view that material adjustments or disclosures, if any, arising out of the forensic audit would be considered after conclusion of the forensic audit and the Management has not estimated the impact of any adjustment that may arise to the amounts and disclosures in the Statement. Consequently, we have not been able to obtain sufficient appropriate audit evidence to state whether any adjustments or disclosure would be required to the information included in the Statement and the impact thereof.
4. Because of the significance of the matter described in paragraph 3 above, we do not have a basis to form an opinion on the Statement and the presentation in accordance with requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



Place: Bengaluru

Date: May 30, 2016

For **Deloitte Haskins & Sells LLP**
Chartered Accountants
Firm's Registration No. 117366W/W-100018

A handwritten signature in black ink, appearing to read "S. Ganesh".

S. Ganesh
Partner
Membership No. 204108

INDEPENDENT AUDITOR'S REPORT

TO THE BOARD OF DIRECTORS OF CAMSON BIO TECHNOLOGIES LIMITED

1. We were engaged to audit the accompanying Statement of Consolidated Financial Results of **CAMSON BIO TECHNOLOGIES LIMITED** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its jointly controlled entity for the year ended March 31, 2016 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared on the basis of the related financial statements. The Holding Company's Management is required to prepare the said financial statements in accordance with the Accounting standards prescribed under section 133 of the Companies Act, 2013, as applicable and other accounting principles generally accepted in India. Refer Note 4 of the Statement.
2. Our responsibility is to express an opinion on the Statement based on conducting our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Because of the matter described in paragraph 3 below, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion.
3. We did not audit the financial statements of two subsidiaries and one jointly controlled entity included in the consolidated financial results, whose financial statements reflect total assets of Rs. 292,622,768 as at March 31, 2016, total revenues of Rs. 369,049,466 for the year ended March 31, 2016, and total loss after tax of Rs. 22,745,360 for the year ended March 31, 2016 as consolidated in the consolidated financial results. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries and jointly controlled entity is based solely on the reports of the other auditors.
4. **Basis for Disclaimer of Opinion:**

We draw attention to Note 4 of the Statement. The Holding Company has received communication from shareholders alleging certain issues relating to financial matters of the Holding Company and have requested to conduct a forensic audit. The Holding Company has replied to the shareholders requesting specific facts and scope/areas for the forensic audit. The Holding Company's Board of Directors has proposed to carry out a forensic audit by appointing an independent committee/legal counsel. As stated in the aforesaid Note, the Holding Company is of the view that material adjustments or disclosures, if any, arising out of the forensic audit would be considered after conclusion of the forensic audit and the Management has not estimated the impact of any adjustment that may arise to the amounts and disclosures in the Statement. Consequently, we have not been able to obtain sufficient appropriate audit evidence to state whether any adjustments or disclosure would be required to the information included in the Statement and the impact thereof.

5. **The Statement:**

(a) Includes the results of the following entities:

- i. Camson Agri Ventures Private Limited
- ii. Camson Agro Products Private Limited
- iii. CAV Chepyala Farms LLP



- (b) Because of the significance of the matter described in paragraph 4 above, we do not have a basis to form an opinion on the Statement and the presentation in accordance with requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.



Place: Bengaluru

Date: May 30, 2016

For Deloitte Haskins & Sells LLP
Chartered Accountants
Firm's Registration No. 117366W/W-100018

A handwritten signature in black ink, appearing to read "S. Ganesh".

S. Ganesh
Partner
Membership No. 204108